{"denoms":[{"counts":[{"groupId":"BG000","value":"251"},{"groupId":"BG001","value":"252"},{"groupId":"BG002","value":"503"}],"units":"Participants"}],"groups":[{"description":"All participants in the Global or China population received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m\\^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"BG000","title":"Placebo + Carboplatin + Etoposide - All"},{"description":"All participants in the Global or China population received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m\\^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"BG001","title":"Atezolizumab + Carboplatin + Etoposide - All"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.0","value":"63.6"},{"groupId":"BG001","spread":"8.8","value":"63.8"},{"groupId":"BG002","spread":"8.9","value":"63.7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"202"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"403"}],"units":"Participants"}],"title":"Global"},{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.8","value":"60.7"},{"groupId":"BG001","spread":"9.0","value":"59.7"},{"groupId":"BG002","spread":"8.9","value":"60.2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"110"}],"units":"Participants"}],"title":"China"}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The intent-to-treat (ITT) population included 503 participants (All) with 403 in the Global population. An additional 100 participants enrolled in the China Extension. The China population included 10 Chinese participants from the Global population plus 100 participants from the China Extension.","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"142"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"261"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"202"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"403"}],"units":"Participants"}],"title":"Global"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"23"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"87"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"110"}],"units":"Participants"}],"title":"China"}],"description":"As reported from Electronic Case Report Form (eCRF).","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Global population included 403 participants. The China population included 100 participants enrolled during the China Extension plus 10 Chinese participants from the Global population.","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"16"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"185"},{"groupId":"BG001","value":"187"},{"groupId":"BG002","value":"372"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"15"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"202"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"403"}],"units":"Participants"}],"title":"Global"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"110"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"110"}],"units":"Participants"}],"title":"China"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The intent-to-treat (ITT) population included 503 participants (All) with 403 in the Global population. An additional 100 participants enrolled in the China Extension. The China population included 10 Chinese participants from the Global population plus 100 participants from the China Extension.","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"69"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"159"},{"groupId":"BG001","value":"163"},{"groupId":"BG002","value":"322"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"202"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"403"}],"units":"Participants"}],"title":"Global"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"110"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"110"}],"units":"Participants"}],"title":"China"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The intent-to-treat (ITT) population included 503 participants (All) with 403 in the Global population. An additional 100 participants enrolled in the China Extension. The China population included 10 Chinese participants from the Global population plus 100 participants from the China Extension.","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"The intent-to-treat (ITT) population included 503 participants (All) with 403 in the Global population. An additional 100 participants enrolled in the China Extension. The China population included 10 Chinese participants from the Global population plus 100 participants from the China Extension. Separate analyses were performed for the Global population and the China population in the study."}